TITLE

Comorbid conditions remain common in patients with HIV and Kaposi's sarcoma

PUB. DATE
September 2008
SOURCE
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p29
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on comorbid conditions in patients with human immunodeficiency virus (HIV) and Kaposi's sarcoma . It references a study by L. Martin-Carbonero et al, which appeared in the 2008 issue of "Clinical Infectious Diseases." The researchers concluded that patients with HIV who were administered pegylated liposomal doxorubicin to treat Kaposi's sarcoma were not likely to have a relapse within a year after cessation of chemotherapy.
ACCESSION #
34154560

 

Related Articles

  • New support group forming at Being Alive.  // Gay & Lesbian Times;4/17/2003, Issue 799, p21 

    Reports on Being Alive's plans to create a support group for people with HIV and Kaposi's sarcoma in San Diego, California.

  • Outcomes of patients with Kaposi's sarcomawho start antiretroviral therapy under routine programme conditions in Malawi. Makombe, Simon D.; Harries, Anthony D.; Kwong-Leung Yu, Joseph; Hochgesang, Mindy; Mhango, Eustice; Weigel, Ralf; Pasulani, Olesi; Fitzgerald, Margaret; Schouten, Erik J.; Libamba, Edwin // Tropical Doctor;Jan2008, Vol. 38 Issue 1, p5 

    AIDS-associated Kaposi's sarcoma (KS) is the most common AIDS-relatedmalignancy in sub-Saharan Africa, with a generally unfavourable prognosis.We report on six-month and 12-month cohort treatment outcomes of human immunodeficiency virus (HIV)-positive KS patients and HIV-positive non-KS patients...

  • Oral Kaposi's sarcoma in a non-HIV homosexual White male. Kua, H. W.; Merchant, W.; Waugh, M. A. // International Journal of STD & AIDS;Nov2004, Vol. 15 Issue 11, p775 

    This paper reports the exceeedingly rare occurrence of oral Kaposi's sarcoma in a non-HIV Caucasian White male. The lesion presented as a 8 mm vascular nodule on the buccal mucosa on the left. He was homosexual. The lesion was removed and histological examination confirmed Kaposi's sarcoma. The...

  • Primary effect of chemotherapy on the transcription profile of AIDS-related Kaposi's sarcoma. Van Der Kuyl, Antoinette C.; Van Den Burg, Remco; Zorgdrager, Fokla; Dekker, John T.; Maas, Jolanda; Van Noesel, Carl J. M.; Goudsmit, Jaap; Cornelissen, Marion // BMC Cancer;2002, Vol. 2, p21 

    Background: Drugs & used in anticancer chemotherapy have severe effects upon the cellular transcription and replication machinery. From in vitro studies it has become clear that these drugs can affect specific genes, as well as have an effect upon the total transcriptome. Methods: Total mRNA...

  • Drug treatment of depression in HIV-positive patients : safety considerations. Pieper, Andrew A.; Treisman, Glenn J. // Drug Safety;2005, Vol. 28 Issue 9, p753 

    Safe and effective treatment of major depression, one of the most common comorbid conditions in individuals infected with HIV, significantly lowers morbidity and mortality from HIV disease. However, optimal treatment of both conditions is complicated by interactions between the disease processes...

  • Long-Term Prognosis of HIV-Infected Patients with Kaposi Sarcoma Treated with Pegylated Liposomal Doxorubicin. Martín-Carbonero, L.; Palacios, R.; Valencia, E.; Saballs, P.; Sirera, G.; Santos, I.; Baldobí, F.; Alegre, M.; Goyenechea, A.; Pedreira, J.; González^del Castillo, J.; Martínez-Lacasa, J.; Ocampo, A.; Alsina, M.; Santos, J.; Podzamczer, D.; González-Lahoz, J. // Clinical Infectious Diseases;8/1/2008, Vol. 47 Issue 3, p410 

    Introduction. Incidence of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV)-infected persons has dramatically decreased in the highly active antiretroviral therapy era. However, this tumor still represents the most common cancer in this population. Objectives. The objectives of this...

  • Combination therapy recommended for patients co-infected with HIV and HCV.  // British Journal of Hospital Medicine (17508460);Sep2010, Vol. 71 Issue 9, p489 

    The article offers information on the new guidance from the National Institute for Health and Clinical Excellence (NICE) that recommends combination therapy with peginterferon alfa and ribavirin as an option for patients who co-infected with HIV or patients with hepatitis C who required...

  • Once-Daily Quadruple-Drug Therapy with Adefovir Dipivoxil, Lamivudine, Didanosine, and Efavirenz in Treatment-Naive Human Immunodeficiency Virus Type 1--Infected Patients. Skowron, Gail; Kuritzkes, Daniel R.; Thompson, Melanie A.; Squires, Kathleen E.; Goodwin, S. Diane; Dusak, Betsy A.; Tolson, Jerry M.; Stevens, Michael; Yuen, Geoffrey J.; Rooney, James F. // Journal of Infectious Diseases;10/1/2002, Vol. 186 Issue 7, p1028 

    A 48-week open-label study of 11 antiretroviral-naive, human immunodeficiency virus type 1 (HIV-1)-infected adults evaluated once-daily treatment with adefovir dipivoxil, lamivudine, didanosine, and efavirenz. At baseline, the median plasma HIV-1 RNA level was 4.99 log[sub 10] copies/mL, and the...

  • Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. La-Beck, Ninh; Zamboni, Beth; Gabizon, Alberto; Schmeeda, Hilary; Amantea, Michael; Gehrig, Paola; Zamboni, William // Cancer Chemotherapy & Pharmacology;Jan2012, Vol. 69 Issue 1, p43 

    Purpose: There is significant inter-patient variability in the pharmacokinetics of pegylated liposomal doxorubicin (PLD). Identification of factors affecting the pharmacokinetics of PLD would enable personalization of therapy. We previously reported that age, gender, body composition, and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics